TABLE 2.

miRNAs associated with exosome-mediated cancer chemoresistance.

Cancer type	miRNAs	Drug-mediated resistance	References
Lung cancer	miR-222-3p	Gemcitabine	Wei et al., 2017
	miR-214	Gefitinib	Zhang Y. et al., 2018
	miR-100-5p	Cisplatin	Qin et al., 2017
Breast cancer	miR-222	Docetaxel	Chen et al., 2014
	miR-567	Truzhuo	Han et al., 2020
	miR-155-3p	Paclitaxel	Au et al., 2016
Ovarian cancer	miR-21	Paclitaxel	Au et al., 2016
	miR-433	Paclitaxel	Weiner-Gorzel et al., 2015
	miR-21-3p	Cisplatin	Pink et al., 2015
	miR-1246	Paclitaxel	Kanlikilicer et al., 2018
	miR-223	Cisplatin	Zhu et al., 2019
Leukemia	miR-365	Imatinib	Min et al., 2018
	miR-19b	Multidrug	Bouvy et al., 2017
	miR-20a	Multidrug	Bouvy et al., 2017
Hepatocellular cancer	miR-32-5p	Multidrug	Fu et al., 2018
Gastric cancer	miR-21	Paclitaxel	Jin et al., 2015
	miR-501	Doxorubicin	Fan et al., 2016; Xu et al., 2018; Liu X. et al., 2019
	miR-522	Cisplatin and Paclitaxel	Zhang et al., 2020
	miR-374-5p	Oxaliplatin	Ji et al., 2019
Oral cancer	miR-21	Cisplatin	Liu et al., 2017
B-cell lymphoma	miR-99a-5p	Doxorubicin	Feng Y. et al., 2019
	miR-125b-5p	Doxorubicin	Fan et al., 2016
Colorectal cancer	miR-92a-3p	5-FU	Hu et al., 2019
Head and neck cancer	miR-196-a	Cisplatin	Qin et al., 2019
Pancreatic cancer	miR-365	Gefitinib	Binenbaum et al., 2018
	miR-210	Gefitinib	Binenbaum et al., 2018
	miR-155	Gefitinib	Patel et al., 2017

5–FU, 5-fluoro-2,4(1H,3H)-pyrimidinedione.